Exosomes in ovarian cancer ascites promote epithelial–mesenchymal transition of ovarian cancer cells by delivery of miR-6780b-5p

Jing Cai, Lanqing Gong, Guodong Li, Jing Guo, Xiaoqing Yi and Zehua Wang

Abstract

The poor prognosis of ovarian cancer is mainly due to metastasis, and the specific mechanism underlying ovarian cancer metastasis is not clear. Ascites-derived exosomes (ADEs) play an important role in the progression of ovarian cancer, but the mechanism is unknown. Here, we found that ADEs promoted ovarian cancer metastasis not only in vitro but also in vivo. This promotive function was based on epithelial–mesenchymal transition (EMT) of ovarian cancer cells. Bioinformatics analysis of RNA sequencing microarray data indicated that miR-6780b-5p may be the key microRNA (miRNA) in ADEs that facilitates cancer metastasis. Moreover, the expression of exosomal miR-6780b-5p correlated with tumor metastasis in ovarian cancer patients. miR-6780b-5p overexpression promoted and miR-6780b-5p downregulation suppressed EMT of ovarian cancer cells. These results suggest that ADEs transfer miR-6780b-5p to ovarian cancer cells, promoting EMT and finally facilitating ovarian cancer metastasis.

Introduction

Ovarian cancer has the highest mortality among gynecologic malignancies. Although the treatment of ovarian cancer has improved in recent years, the five-year survival rate of ovarian cancer patients, which has remained at approximately 40%, has not improved significantly in the last twenty years—the survival rate in the last five years was only 41.8%. Metastasis, nonspecific symptoms at early tumor stages and chemoresistance may be the main reasons for the poor prognosis of ovarian cancer. Ovarian cancer patients generally manifest symptoms only after progression to an advanced stage, and only a few women are diagnosed before the tumor metastasizes to the peritoneal cavity. More than 70% of ovarian cancer patients are at a late stage with peritoneal metastasis and are diagnosed with advanced-stage disease, resulting in a high risk of death. Thus, it is imperative to illustrate the underlying molecular mechanisms behind tumor metastasis and guide the therapeutic strategy of ovarian cancer to improve prognosis. Implantation metastasis to the omentum and peritoneal organs is the most common form of ovarian cancer metastasis. Peritoneal metastasis is often accompanied by the accumulation of malignant ascites, while the formation of omental metastasis with ascites accelerates tumor progression. However, the facilitative role of ascites in tumor metastasis is still unclear. Therefore, it is important to determine the mechanism by which ascites promotes ovarian cancer metastasis.

Exosomes are extracellular vesicles with diameters of 50–140 nm that can carry small molecules, such as nucleic acids, proteins, and other bioactive molecules, to communicate between cells. Exosomes secreted by tumor cells can promote tumor growth, metastasis, and angiogenesis and participate in the drug resistance of tumor cells. High levels of exosomes have been found...
in the culture supernatant of ovarian cancer cells and ascites from ovarian cancer patients. Ascites-derived exosomes (ADEs) from ovarian cancer patients were found to be significantly correlated with tumor load, invasion, and short survival time\(^\text{11}\). Exosomes from ovarian cancer patients were also found to promote interstitial barrier clearance by peritoneal interstitial cells\(^\text{12}\). These results suggest that ADEs play an important role in the metastasis of ovarian cancer. Exosomal microRNAs (miRNAs) play an important role in the biological actions of ovarian cancer because these molecules are specific and closely related to the cell type and state\(^\text{13}\). For example, miR-6126 acts as a tumor suppressor by directly targeting integrin β1 and inhibits ovarian cancer cell metastasis\(^\text{14}\), and miR-6086 inhibits ovarian cancer angiogenesis\(^\text{15}\), while miR-21–3p, miR-125 b-5p, miR-181 d-5p and miRNA-205 in ovarian cancer exosomes promote tumor invasion and metastasis\(^\text{16,17}\). The serum miRNA profiles of patients with ovarian carcinoma constituted a promising diagnostic biomarker for ovarian cancer in a recent study\(^\text{18}\). Therefore, identification of the key miRNAs in ADEs is expected to contribute to clarifying the mechanism underlying ovarian cancer metastasis and help to identify therapeutic targets for ovarian cancer.

Cancer metastasis involves multiple steps, including the epithelial–mesenchymal transition (EMT)\(^\text{19}\). The conversion of an epithelial cell to a mesenchymal cell plays a key role in the invasion and metastasis of ovarian cancer\(^\text{20,21}\). In the present study, in vitro and in vivo experiments were conducted to verify the promotive effect of ADEs on ovarian cancer metastasis. The role of ADEs was validated in cancer cell lines and primary tumor cells. EMT markers were detected to determine whether ADEs affect EMT in ovarian cancer. Bioinformatics analysis of RNA sequencing microarray data indicated that miR-6780b-5p may be the key miRNA in ADEs that facilitates ovarian cancer metastasis. Moreover, the correlation of miR-6780b-5p with tumor metastasis was validated in ascites from ovarian cancer patients. Tumor cell migration and EMT markers were evaluated after miR-6780b-5p expression was regulated by transfection with an agomir or antagonir. We demonstrated the effects of miR-6780b-5p in ADEs as promoting EMT of ovarian cancer cells and finally facilitating ovarian cancer metastasis.

**Materials and methods**

**Ascites specimens and primary cells**

All ascites specimens of patients with ovarian cancer were collected from patients who underwent surgery for the first time at the Union Hospital of Tongji Medical College, Huazhong University of Science and Technology from October 2014 to October 2016, while cancer tissues that were surgically removed from two patients with high-grade serous ovarian carcinoma (HGSOCC) were used for the culture of primary tumor cells. No patients had received radiotherapy or chemotherapy before the surgery, and all were pathologically diagnosed with ovarian cancer. The pathological characteristics of ovarian cancer patients whose ascites were collected are listed in Table 1. Fresh ascites was centrifuged at 300 × g for 10 min to remove cell components, and the cell components were collected and stored at −80 °C. Then, the supernatant was used for exosome extraction or stored at −80 °C. The pathological characteristics of ovarian cancer patients whose tissues were used for primary tumor cell culture are listed in Table 2. Primary tumor cells were extracted using the collagenase treatment method as described previously\(^\text{22}\) and cultured in DMEM/F12 medium supplemented with 10% fetal bovine serum (FBS, Gibco). All primary tumor cells were used for a maximum of three passages as previously described\(^\text{22}\). All procedures were conducted with the approval of the Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology. Patient consent was obtained before the start of the study.

**Cell culture and processing**

The human ovarian cancer cell lines A2780, SKOV3, CAOV3, and ES2 were purchased from the cell bank of the Chinese Academy of Sciences and cultured in DMEM/F12 medium supplemented with 10% FBS (Gibco). A2780 is a human ovarian cancer cell line, CAOV3 is a human papillary ovarian adenocarcinoma cell line, while ES2 is a human clear ovarian cell line and SKOV3 is a human ovarian adenocarcinoma cell line. All cell lines were cultured in a humidified incubator at 37 °C in 5% CO₂ and were authenticated by short tandem repeat (STR) profiling and confirmed to be mycoplasma negative. For exosome processing, ovarian cancer cells were grown to a density of approximately 70% and washed with phosphate buffer saline (PBS) twice to exclude the interference of abundant exosomes in serum. The cancer cells were then cultured with exosome-free serum, and 0 μg/ml, 50 μg/ml, and 100 μg/ml ADEs were added to the culture medium. After 48 h of culture, the cancer cells were collected for subsequent experiments.

**Isolation of ADEs**

For the separation of ascites exosomes, we used the classic ultracentrifugation method. The ascites was first centrifuged at 300 × g for 10 min, and cell pellets were collected and stored at −80 °C for subsequent immunohistochemistry analysis about cell components. The supernatant was further centrifuged at 2000 × g for 20 min, filtered through 0.22-μm filters (Millipore), centrifuged twice with an Optima MAX-XP centrifuge (Beckman Coulter) at 100,000 × g for 70 min, and
| ID | Age (year) | FIGO stage | Pathological type                | CA125 U/ml | Tumor size                       | Peritoneal metastasis | Relative miR-6780b-5p level |
|----|------------|------------|----------------------------------|------------|----------------------------------|-----------------------|---------------------------|
| #1 | 60         | IIIC       | Clear cell carcinoma             | 351.2      | 11.3 cm×11.3 cm×10.1 cm          | No                    | 45.88                     |
| #2 | 61         | IIIC       | High-grade serous carcinoma      | 1200       | 10 cm×10 cm×8 cm                 | Yes                   | 81.63                     |
| #3 | 51         | IIIC       | High-grade serous carcinoma      | 1000       | 3.1 cm×2.2 cm                    | Yes                   | 482.18                    |
| #4 | 37         | IC         | Mucinous cystadenocarcinoma       | 92.4       | 19 cm×14 cm×4 cm                 | No                    | 1.00                      |
| #5 | 40         | IV         | High-grade serous carcinoma      | 600        | 8.1 cm×5.3 cm×4.6 cm, 6.3 cm×5.0 cm×4.6 cm | No                    | 4.87                      |
| #6 | 72         | IIB        | High-grade serous carcinoma      | 1200       | 3 cm×3 cm                        | No                    | 55.78                     |
| #7 | 43         | IC         | High-grade serous carcinoma      | 1475       | 8.4 cm×10 cm×7.9 cm              | Yes                   | 149.93                    |
| #8 | 23         | IC         | Borderline serous tumor          | 1200       | 7.5 cm×6.7 cm×4.4 cm             | No                    | 7.01                      |
| #9 | 42         | IV         | High-grade serous carcinoma      | 1200       | 30 cm×25 cm                      | Yes                   | 390.38                    |
| #10| 24         | IIIC       | Borderline serous tumor          | NA         | 7.3 cm×6.1 cm, 8.8 cm×6.4 cm     | Yes                   | 275.34                    |
| #11| 45         | IIIC       | High-grade serous carcinoma      | 850.8      | 15 cm×15 cm                      | Yes                   | 49.54                     |
| #12| 45         | IIIB       | High-grade serous carcinoma      | 1200       | 6 cm×5 cm                        | Yes                   | 25.03                     |
| #13| 59         | IIIC       | High-grade serous carcinoma      | 1200       | 7.6 cm×6.9 cm×6.3 cm             | Yes                   | 2.88                      |
| #14| 52         | IC         | Clear cell carcinoma             | 4042.5     | 16.1 cm×12.7 cm×13.6 cm          | No                    | 6.23                      |
| #15| 52         | IC         | Follicular cell tumor            | 1200       | 13.0 cm×15.0 cm                  | No                    | 65.50                     |
| #16| 47         | IIIC       | High-grade serous carcinoma      | NA         | 24.5 cm×14.5 cm×11.5 cm          | Yes                   | 24.39                     |
| #17| 48         | IV         | High-grade serous carcinoma      | 1200       | 7.6 cm×4.5 cm×8.0 cm, 8.9 cm×7.6 cm×9.0 cm | No                    | 2.71                      |
| #18| 34         | IV         | Clear cell carcinoma             | 431        | 21.2 cm×18.6 cm×12.7 cm          | Yes                   | 18.04                     |
| #19| 54         | IA         | Borderline mucinous tumor        | 69.5       | 9.6 cm×10.1 cm×12.4 cm           | No                    | 46.12                     |
| #20| 36         | IV         | Endometrioid adenocarcinoma      | 1200       | 8.2 cm×4.7 cm×5.6 cm             | Yes                   | 14.81                     |
| #21| 47         | IIIB       | High-grade serous carcinoma      | 3000       | 7.1 cm×6.3 cm×5.7 cm             | Yes                   | 97.86                     |
| #22| 43         | IIIC       | High-grade serous carcinoma      | 1200       | 4.8 cm×5.7 cm×3.2 cm, 3.1 cm×3.7 cm×2.8 cm | Yes                    | 18.18                     |
| #23| 65         | IIIC       | Poorly differentiated neuroendocrine carcinoma | 1200   | NA                                | Yes                   | 50.25                     |
| #24| 41         | IV         | High-grade serous carcinoma      | 1200       | 10.0 cm×8.6 cm×6.3 cm, 7.2 cm×6.8 cm×6.5 cm | Yes                    | 339.63                    |
| #25| 59         | IIIC       | High-grade serous carcinoma      | 1200       | 3.9 cm×2.7 cm, 3.5 cm×4.4 cm×2.0 cm | Yes                    | 179.95                    |
| #26| 11         | IIIC       | Yolk sac tumor                   | 410.6      | 14 cm×11 cm×13 cm                 | Yes                   | 102.15                    |
| #27| 61         | IIIC       | High-grade serous carcinoma      | 1200       | 3 cm×3 cm×2 cm                   | Yes                    | 23.09                     |

FIGO International Federation of Gynecology and Obstetrics, NA not available.
dissolved in PBS. Exosomes were used or stored at 
−80 °C. Considering that HGSOC is the most common 
pathology type in ovarian cancer and accounts for 
70–80% of ovarian cancer deaths3, ADEs #2, #3, #6, #7, 
#12, #21, #25, and #27, which derived from HGSOC 
patients, were chosen to conduct most of the experiments. 
ADEs were used throughout the study because there was a large amount of ascites available, which provided us 
with abundant exosomes for the experiments. The protein 
concentration of exosomes was determined by a 
bicinchoninic acid (BCA) protein kit (Beyotime).

Transmission electron microscopy (TEM) 
Exosomes were observed by TEM using negative 
staining with copper mesh as in a previous study23. Exo-
somes were dissolved in 10 μl of PBS and then dripped on 
a copper mesh with a diameter of 2 nm. The sample was 
adried for several minutes at room temperature, 
exposed to 20 μl of phosphotungstic acid solution at a 
concentration of 3% for several minutes, and then dried at 
room temperature. The shape and size of the exosomes 
were finally observed with a MegaView G2 transmission 
electron microscope.

Dynamic light scattering (DLS) and NanoSight analysis (NTA) 
DLS analysis and NTA analysis were performed in a 
Zeta Potential Analyzer instrument (Colloidal Dynamics, 
USA) and a NanoSight NS300 instrument (Malvern, UK). 
The samples were added to the instrument to analyze the 
diameter and concentration of exosomes.

Flow cytometry 
Flow cytometric analysis of the surface marker of exo-
somes was conducted as described previously24. Three 
microliters of latex microspheres (aldehyde/sulfate latex 
beads, Invitrogen) were added to exosomes with 40 μg of 
protein and gently mixed for 2–3 h at room temperature. 
Then, 1 M glycine was added and mixed upside down for 
0.5 h to block the reaction, and the sample was cen-
drifuged at 300 × g for 10 min. Then, PBS was added and 
centrifuged to wash away unbound antibody. Primary 
antibodies against CD63 and CD9 were added and mixed 
at 4 °C overnight, while rabbit IgG was used as an isotype 
control. The samples were washed with PBS twice, 
reacted with a fluorophore-conjugated secondary antibod-
ny at room temperature for 1 h, and detected by flow 
cytometry.

Exosome uptake assay 
For exosome uptake experiments, freshly isolated exo-
somes were stained with a PKH67 Green Fluorescent Cell 
Linker Mini Kit (Sigma), and the procedure was con-
ducted according to the instructions. PKH67-pretreated 
exosomes were added to the cells in culture, and culture 
was continued for 24 h in the dark. Recipient cells were 
incubated with phallotoxins (Invitrogen Life Technolo-
gies) and reacted for 60 min at room temperature. Finally, 
the cells were imaged under a fluorescence microscope.

Migration and invasion assays 
A total of 4×10⁴ or 8×10⁴ cancer cells treated with or 
without ADEs were plated in 24-well transwell plates with 
inserts (8 μm in diameter, Corning) with or without 
Matrigel. The medium in the inserts did not contain FBS, 
whereas the medium outside of the inserts was supple-
mented with 10% FBS. After 24 h, the cell inserts were 
fixed with formaldehyde, stained with 0.1% crystal violet, 
observed and imaged under a microscope.

Wound-healing assay 
For the wound-healing assay, equal numbers of cells 
treated with ADEs were plated into six-well plates. The 
cell monolayers were wounded with a pipette tip to create 
a gap on the plates. After washing the cells gently with 
PBS to remove floating cells, the culture medium was 
replaced with serum-free medium to inhibit cell pro-
liferation, and cancer cells were allowed to close the 
wound for 24 h. The area of wound closure after the first 
scratch (0 h) and after 24 h (24 h) was observed and 
measured by microscopy with Image-Pro Plus 6 software 
(Media Cyberbetics, USA).

F-actin immunofluorescence 
The F-actin immunofluorescence analysis of ovarian 
cancer cells was conducted as described previously25. The 
cells were fixed with 4% formaldehyde and washed with 
PBS three times for 5 min each. Then, phallotoxins 
(Invitrogen Life Technologies) were added and reacted for 
60 min. Subsequently, the cell nuclei were stained with

| Patient | Age (years) | FIGO stage | Histological type | Neoadjuvant chemotherapy | Tumor size | Chemotherapy |
|---------|-------------|------------|------------------|--------------------------|------------|--------------|
| T1      | 58          | IIIC       | High-grade serous carcinoma | NO | 12.0 cm × 10.0 cm × 6.5 cm | TP |
| T2      | 68          | IIIC       | High-grade serous carcinoma | NO | 5.6 cm × 5.6 cm × 5.2 cm | TP |

*FIGO International Federation of Gynecology and Obstetrics, TP, chemotherapy based on paclitaxel and platinum.*
DAPI. The cell morphology was imaged under a fluorescence microscope.

Western blotting
The protein concentration of exosomes was directly measured with BCA assay. Total cellular protein was extracted with radioimmunoprecipitation assay (RIPA) buffer including a protease inhibitor cocktail for 30 min and centrifuged at 13,000 × g for 10 min to collect supernatants, and the protein concentration was measured with BCA assays. Samples were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes. Membranes were then blocked with 5% nonfat milk in Tris-buffered saline with Tween 20 (TBST) for 1 h at room temperature and incubated with primary antibodies specific for the following proteins at 4 °C overnight: CD63 (1:1000 dilution, Abcam, ab134045, USA); CD9 (1:1000 dilution, Abcam, ab92716, USA); calnexin (1:2000 dilution, Abcam, ab133615, USA); E-cadherin (1:3000 dilution, CST, #3195 S, USA); N-cadherin (1:1000 dilution, CST, #13116 S, USA); Vimentin (1:1000 dilution, CST, #5741 S, USA); PAX8 (1:5000 dilution, Proteintech, 10336-1-AP, USA); cytokeratin 8 (1:500 dilution, Abcam, ab53280, USA); calretinin (1:1000 dilution, Abcam, ab92341, USA); α-SMA (1:5000 dilution, Abcam, ab5694, USA); and β-actin (1:5000 dilution, Proteintech, 66009-1-Ig, USA). Chemiluminescence detection of protein bands was performed using horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies, and the protein bands were detected with an enhanced chemiluminescence kit (Pierce) in a Molecular Imager® ChemiDoc™ XRS+ system with Image Lab™ software (Bio-Rad).

Immunofluorescence
The experimental immunofluorescence procedure was the same as that previously described.26 Slides with cells were washed three times and fixed with 4% paraformaldehyde. After three washes with PBS, the slides were reacted with 0.1% Triton X for 30 min to disrupt the cell membrane and 1% BSA for 30 min to block the antigen at room temperature and were then incubated with the primary antibodies at 4 °C overnight. Then, the slides were washed with PBS on a shaking bed at room temperature for 5 min; this step was repeated 3 times. The slides were then incubated with fluorescence-labeled secondary antibodies for 1 h at room temperature. DAPI was added and incubated for 30 min at room temperature to stain nuclei. After three washes, the cells were imaged under a fluorescence microscope. For membrane proteins, that is, E-cadherin and N-cadherin, the cells were fixed, and the primary antibody was added without disrupting the membrane. After the primary antibody was washed off on the second day, 0.1% Triton X-100 was added, and the following steps were the same as those for cytoplasmic proteins.

5-ethyl-2'-deoxyuridine (EdU) cell proliferation assay
Cancer cells treated with ADEs were digested with trypsin and inoculated in 96-well plates. The EdU cell proliferation assay was conducted according to the instructions of the EdU kit (RiboBio, China). The results were observed and imaged with a fluorescence microscope. The experiment was repeated three times.

Colony formation assay
Cancer cells treated with ADEs were digested with trypsin and inoculated in 6-well plates at 1000 cells per well. After 7-10 days of culture, the cells grew into visible colonies. The plates were gently washed two times with PBS, fixed for 20 min with 4% polyformaldehyde at room temperature, washed two times with PBS, and stained for 30 min with 0.1% crystal violet at room temperature. The experiment was repeated three times.

RNA extraction and qRT-PCR
Total RNA was extracted from cells using TRIzol reagent (TaKaRa, Japan) according to the manufacturer’s instructions, and purification of miRNAs from exosomes and qRT-PCR were performed as described previously.27 Reverse transcription was performed using a miRNA reverse transcription kit (Toyobo, Japan) and random primers. Real-time fluorescence quantitative PCR with SYBR Green was carried out in an Applied Biosystems Plus PCR System (ABI). All miRNA primers were designed and synthesized by RiboBio (China). The expression of intracellular miRNA was normalized to that of U6 as the internal reference gene, while the expression of exosomal miRNA was normalized to that of miR-16 as the internal reference miRNA.28 Each reaction was performed in triplicate, and the experiment was repeated three times.

Orthotopic xenograft mouse model of ovarian cancer
All mice used to establish the orthotopic xenograft mouse model of ovarian cancer were housed in the experimental animal center of Tongji Medical College, Huazhong University of Science and Technology. All procedures followed the operational specifications of the animal management committee. Four- to six-week-old female BALB/c nude mice were purchased from Beijing Hua Fukang Biological Polytron Technologies, Inc. The ovarian cancer cell line SKOV3 was transduced with a lentiviral luciferase reporter gene, screened with puromycin, and selected for monoclonal cells, which were termed SKOV3-luc+ cells. SKOV3-luc+ cells in...
logarithmic growth phase were digested with trypsin, suspended in serum-free medium, and used at a density of 5×10^8 cells/ml. Nude mice were completely anesthetized (4% chloral hydrate, 0.1 ml/10 g body weight) and placed in the lateral position. An incision in the peritoneum was made in the left abdomen. The incision was made parallel to the spinal column, and the length was 1 cm. After the left ovary was exposed, 5 µl of cell suspension was injected gently, slowly, and meticulously into the ovary to avoid leakage and capsule rupture. The ovarian cavity was returned to the abdominal cavity, and the peritoneum and skin were sutured layer by layer. Approximately 30 min after the operation, the mouse was revived, and observation was continued.

Effect of ADEs on ovarian cancer in vivo

The orthotopic xenograft mouse model and bioluminescence live imaging were used to detect the effect of ADEs on ovarian cancer in vivo. Twelve nude mice were randomly divided into two groups with 6 mice in each group. The first day after inoculation of SKOV3-luc+ cells into the nude mice, one group received 50 µg of ADEs by intraperitoneal injection every three days, while the control group received PBS by intraperitoneal injection. The first bioluminescence live imaging was performed 7 days after inoculation. The nude mice were anaesthetized with 2% isoflurane and 1.5 L/min oxygen and injected intraperitoneally with D-luciferin at a dose of 150 mg/kg. Ten minutes after substrate injection, the nude mice were placed in the imaging room in the prone position. The intensity and location of luminescence were detected with a live imaging biological instrument. Whole-body live imaging was conducted once a week for 8 weeks.

Immunohistochemistry (IHC)

Immunocytochemical analysis of E-cadherin, N-cadherin, and vimentin in orthotopic tumor tissues of nude mice was conducted as previously described 29. Paraffin slides were dehydrated three times with TO clarifier for biological tissue slicing and dehydrated through a gradient ethanol series. Antigen retrieval was performed for 20 min in 0.01 M citric acid solution at 95 °C. Then, 3% H_2O_2 and normal sheep serum were used to quench endogenous peroxidase activity and block the antigen, respectively. The tissues were incubated with primary anti-E-cadherin, anti-N-cadherin, anti-Vimentin and anti-Ki67 (Abcam, ab15580, USA) antibodies at 4 °C overnight prior to incubation with a biotinylated goat anti-rabbit antibody for 1 h at room temperature. Immunostaining was performed with diaminobenzidine (DAB). Normal rabbit IgG was used as a negative control, and positive expression was defined as brown-yellow granules distributed in the cytoplasm, nucleus or cytomembrane. Ki67 immunoreactivity was assessed according to the average percentage of positively stained cells in five randomly selected fields. The immunoreactivity scores for E-cadherin, N-cadherin and Vimentin were determined by Image-Pro Plus, version 6.0 (Media Cyberbetics, USA) as follows: Mean Density = Integrated Optical Density/Area of DAB staining 30.

Survival analysis of miR-6780b-5p in ovarian cancer patients

To determine the prognostic significance of miR-6780b-5p in ovarian cancer patients, we used the online microarray data analysis website K-M Plotter 31 to investigate the prognostic significance of miR-6780b-5p in pancancer datasets. “miRNA-pancancer analysis” was selected. “miR-6780b” was entered as gene symbol, and the “Auto select best cut off” button was selected. Kaplan–Meier and log-rank test were used to evaluate differences in overall survival (OS) time.

Statistical analysis

Statistical analysis was performed using SPSS 17.0 statistical software and GraphPad Prism 5.0 software. Numerical data are expressed as the mean ± standard deviation (s.d.) values. Student’s t test or one-way analysis of variance was used to evaluate the differences between two or multiple groups, respectively; p < 0.05 was considered significant.

Results

ADEs enter ovarian cancer cells

The four kinds of ADEs used in the subsequent experiments, which were obtained from four HGSOC patients, including #2, #3, #7 and #27, were characterized and quantified by TEM, Western blot analysis, DLS, NTA and flow cytometry. And the cell pellets from #7 and #27 patients were detected by immunohistochemistry to show the cell components in the ascites. ADEs appeared as round vesicles with a double layer, and a diameter of 50-140 nm under an electron microscope (Fig. 1a, Supplementary Fig. 1a), consistent with the NTA and DLS analysis results (Fig. 1c, d, Supplementary Fig. 1c, d). Western blot analysis showed that CD63 and CD9, markers of exosomes, were highly expressed in ADEs compared with cell pellets, while calnexin, a negative control for exosomes 32,33, was not present in ADEs but existed in cell pellets (Fig. 1b, Supplementary Fig. 1b). Furthermore, we used flow cytometry to analyze the expression of surface marker proteins of ADEs. We found that ADEs from different patients displayed diverse expression of surface marker proteins. For example, ADEs #2 and #3 expressed high levels of CD63, with positive rates of 85.23% and 51.07%; in addition, the positive rates of CD9 expression were 16.23% and 24.54%, respectively (Fig. 1e).
To confirm whether ADEs can enter ovarian cancer cells, we used PKH67 to label #7 ADEs and conducted immunofluorescence to track the location of ADEs in ovarian cancer cells. The results showed that green fluorescently labeled ADEs could enter SKOV3, A2780, CAOV3 and ES2 cells (Fig. 1f, Supplementary Fig. 2). In addition, IHC analysis of cell pellets from #7 and #27 ascites were conducted to explore the origin cells of ADEs. It showed that various cell types existed in the ascites, including cancer cells, CAFs, and macrophagocytes (Supplementary Fig. 3), implying ADEs may be secreted by those cells.

ADEs promote EMT of ovarian cancer cells in vitro

To clarify the effects of ADEs on the invasion and migration of ovarian cancer cells, #7 ADEs extracted from a HGSOC patient were chosen to explore the effects of ADEs on three ovarian cancer cell lines, that is, A2780 and CAOV3 cells, which had reduced tendency to metastasize, and SKOV3 cells, which was more capable of metastasis. Wound-healing assays and transwell migration and invasion assays showed that ADEs significantly promoted the migration and invasion of each cell line in vitro in a concentration-dependent manner (Fig. 2a–c), while CAOV3 cells were absent because their invasion and migration abilities were too low to pass through the transwell membranes or moved closer. We also found that A2780 and CAOV3, which seemed to be more similar to epithelial phenotype and had relatively reduced tendency to metastasize, acquired an elongated, dispersed, and more spindle-shaped morphology after treatment with the

Fig. 1 ADEs enter ovarian cancer cells. a Electron micrograph of the exosomes extracted from ascites of patient #2. Scale bar, 200 nm. b Western blot analysis of CD63, CD9 and calnexin in ADEs #2 and #3 as well as in the cell pellet control. c Size analysis of the ADEs #2 and #3 using NTA. d Size analysis of ADEs #2 and #3 using DLS analysis. e Flow cytometric analysis of the expression of CD63 and CD9 in ADEs #2 and #3. f Immunofluorescence detection of ADE uptake by SKOV3 cells. In exosomes, PKH67 was labeled with green, and F-actin was labeled red; nuclei were labeled with DAPI (blue). Scale bar, 20 μm.
Fig. 2 ADEs promote EMT of ovarian cancer cells in vitro. A2780, CAOV3, ES2 and SKOV3 ovarian cancer cells were treated with 0 µg, 50 µg, and 100 µg of #7 ADEs. Representative images of wound-healing assays of A2780 and SKOV3 and the area of wound closure was measured. Scale bar, 100 µm. Representative images from migration and invasion assays of A2780 and SKOV3 cells. Scale bar, 100 µm. Invaded and migrated cells were counted and are shown as histograms. Changes in the morphology of A2780 and CAOV3 cells were evaluated by microscopic observation and F-actin staining. Scale bar, 100 µm (d). Scale bar, 20 µm (e). Western blot analysis of E-cadherin, N-cadherin, and Vimentin expressions in A2780, CAOV3, ES2 and SKOV3 cells. Immunofluorescence analysis of E-cadherin, N-cadherin, and Vimentin in A2780 and CAOV3 cells. Experiments were performed in at least triplicate, and the results are shown as the mean ± s.d. values. Student’s t-test was used to analyze the data (NS, not significant; *p < 0.05; **p < 0.01; ***p < 0.001). Scale bar, 20 µm.
Fig. 3 (See legend on next page.)
ADEs (Fig. 2d, e), indicating the probable role of ADEs in EMT. The Western blot and immunofluorescence results showed that the #7 ADEs facilitated EMT of ovarian cancer cells (Fig. 2f, g), consistent with the results for #27 ADEs (Supplementary Fig. 4). In addition, the EdU cell proliferation and colony formation assays indicated that ADEs accelerated the proliferation of ovarian cancer cells (Supplementary Fig. 5).

**ADEs promote EMT and metastasis of ovarian cancer cells in vivo**

To further explore the effects of ADEs on the metastasis of ovarian cancer in vivo, we established an orthotopic xenograft model of ovarian cancer in nude mice. In vivo imaging technology was used to continuously observe the growth and metastasis of ovarian cancer. Two sets of ADEs from two HGSOC patients, i.e., ADEs #7 and #27, were intraperitoneally injected every three days. The results showed that intraperitoneal injection of #7 ADEs accelerated tumor growth (Fig. 3a, b) and metastasis to the abdominal organs (Fig. 3c, d). Mice in the ADE-treated group had larger tumors and more peritoneal metastases than those in the control group (Fig. 3e, f). These results demonstrated that ADEs promote ovarian cancer metastasis. We also conducted immunohistochemical analysis of E-cadherin, N-cadherin, and Vimentin in tumor tissues of orthotopic xenograft model mice and verified that ADE treatment decreased the expression of E-cadherin and increased the expression of N-cadherin and Vimentin in the orthotopic tumors (Fig. 3g, e), indicating the transition of cells from an epithelial to a mesenchymal phenotype in the tumor tissue. The same effect was observed with the #27 ADEs (Supplementary Figure 6).

**ADEs promote EMT of primary tumor cells**

We confirmed that ADEs promote ovarian cancer cell invasion and metastasis in vitro and in vivo by facilitating EMT in cancer cells. To further clarify the effect of ADEs on primary tumor cells extracted from patient’s tissue, we detected the impact of ADEs on cell migration and proliferation. Surgically removed cancer tissues from two HGSOC patients was used to culture primary tumor cells, which showed a characteristic cobblestone appearance before treatment with ADEs (Supplementary Fig. 7a). Western blot analysis, flow cytometry and immunohistochemical staining for specific markers confirmed the epithelial nature of the primary cells as well as the absence of other contaminating cell types (Supplementary Fig. 7b–d). After treatment with #7 ADEs, the primary tumor cells (T1 and T2) became slender and dispersed (Fig. 4a), and the migration as well as proliferation of the primary tumor cells was accelerated by ADE treatment (Fig. 4b–g). ADE treatment decreased the expression of E-cadherin and increased the expression of N-cadherin and Vimentin in the primary tumor cells (Fig. 4h).

**ADEs transfer miR-6780b-5p to ovarian cancer cells**

Data mining based on public databases is currently a popular approach. We searched the ovarian cancer exon chip information in the Gene Expression Omnibus (GEO) public database and downloaded the data set GSE76449, a noncoding RNA profiling array of 6 different ovarian cancer cell lines and one normal ovarian cell line. Bioinformatics analysis of GSE76449 was performed, and 25 miRNAs were found to be more highly expressed in exosomes from the highly metastatic SKOV3-ip1 and HEYA8 cell lines than in exosomes from low-metastatic A2780 cells. Seven candidate miRNAs were the most abundant among the 25 miRNAs (miR-6780b-5p, miR-122-5p, miR-1246, miR-1281, miR-1290, miRNA-4484, and miR-1825) (Fig. 5a, b). To determine which miRNA can be transferred from ADEs to ovarian cancer cells, we used qRT-PCR to detect the expression of the seven miRNAs in A2780 and CAOV3 cells treated with #7 ADEs and #27 ADEs. The results showed that the miR-6780b-5p level increased in a concentration-dependent manner (Fig. 5c), suggesting that miR-6780b-5p may be transferred to ovarian cancer cells by ADEs. Considering that miR-6780b-5p is a new miRNA, we predicted the target genes and functions of miR-6780b-5p with three online miRNA target analysis websites (TargetScan, miDB and RNA22) (Fig. 5d). Gene Ontology (GO) analysis of miR-6780b-5p target genes showed that miR-6780b-5p may play important roles in many pathophysiological processes, including intercellular signal transduction, transcriptional regulation, and protein binding (Fig. 5e). Moreover, Kyoto Encyclopedia of Genes and
Fig. 4 (See legend on next page.)
miR-6780b-5p promotes EMT in ovarian cancer cells

To clarify the effect of miR-6780b-5p on ovarian cancer, we detected miR-6780b-5p expression in exosomes from 27 ovarian cancer patients. We found that miR-6780b-5p expression was higher in patients who had peritoneal metastasis than those who did not (Fig. 6a). Among the 27 ADEs, 7# ADEs had relatively high expression of miR-6780b-5p (Table 1 and Fig. 6a). In the pancancer miRNA analysis conducted with K-M Plotter44, high miR-6780b expression indicated a poor patient survival (Fig. 6b), though the online analysis tool did not distinguish between −3p and the −5p miRNA. The result supports the hypothesis that miR-6780b-5p relates to poor patient survival to some extent. Moreover, we found that miR-6780b-5p expression was higher in SKO3 and ES2 cells than in A2780 and CAOV3 cells, which have comparatively low migration and invasion abilities (Fig. 6c). To further investigate whether miR-6780b-5p affects EMT of ovarian cancer cells, four sets of ADEs from four HGSOC patients, ADEs #6, #12, #21, and #27, with different miR-6780b-5p concentrations, were used (Fig. 6d). Western blotting revealed that the E-cadherin level in A2780, CAOV3, ES2, and SKO3 cells was decreased to varying degrees, while the N-cadherin and Vimentin levels were increased, in a miR-6780b-5p level-dependent manner (Fig. 6e). For instance, #25 ADEs had the highest level of miR-6780b-5p, and the corresponding changes in E-cadherin, N-cadherin, and Vimentin levels in ovarian cancer cells after treatment were substantially larger than the changes after treatment with #6, #12, or #21 ADEs, which had relatively low levels of miR-6780b-5p. To further verify the function of miR-6780b-5p in EMT, we used a miRNA agomir and antagomir to alter miR-6780b-5p expression in ovarian cancer cells. The regulatory efficiency was confirmed by qRT-PCR (Fig. 6f). We found that the cancer cells acquired an elongated, dispersed, and more spindle-shaped morphology after treatment with the miR-6780b-5p agomir (Supplementary Fig. 8); moreover, upregulation of miR-6780b-5p promoted and downregulation of miR-6780b-5p suppressed the migration of ES2 and SKO3 cells (Fig. 6g, h). Western blot analysis showed that upregulation of miR-6780b-5p decreased the expression of E-cadherin and increased that of N-cadherin and Vimentin and that downregulation of miR-6780b-5p had the opposite effects (Fig. 6i). These results suggested that miR-6780b-5p promotes EMT of ovarian cancer cells.

Discussion

Intraperitoneal spread of a malignancy is orchestrated by a reciprocal interplay between various cells in the tumor microenvironment, including cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), peritoneal mesothelial cells (PMCs), etc. Because ascites fluid is one of the major contributors to this interaction in the malignancy of ovarian cancer, understanding the signal transduction and interactions between ascites fluid and tumor cells in the tumor microenvironment is extremely important. Consistent with previous studies11, a large number of exosomes was found in the ascites of ovarian cancer patients and was shown to contribute to tumor progression in our study. Currently, several studies have focused on a single type of exosome from specific kinds of cells. For example, cancer-associated adipocytes (CAAs) and CAFs stimulate ovarian cancer cell motility and invasion via miR-21 delivery23. TAM-derived exosomes transfer miR-29a-3p and miR-21-5p to synergistically induce a Treg/Th17 cell imbalance and drive the progression and metastasis of epithelial ovarian cancer (EOC)37. Conversely, exosomes derived from hypoxic EOC cells deliver miRNAs to TAMs and elicit a tumor-promoting phenotype16. These findings indicate that cells in the intraperitoneal microenvironment transduce signals and interact with each other. Consistent with previous research38, we found that various cell types exist in the ascites population, including cancer cells, CAFs and macrophagocytes (Supplementary Fig. 3). Consequently, the ultimate function of ascites or ADEs on tumor biological behavior may be a superposition of effects because ADEs come from these...
Fig. 5 (See legend on next page.)
different cells, while the cancer cells are likely the biggest contributor because they were the main composition of ascites cells (Supplementary Fig. 3). However, no common exosomal miRNA in exosomes from different cells was identified in the present, which increases the difficulty in using a specific miRNA as a therapeutic target to achieve maximum inhibition of tumor metastasis. In our study, we showed that ADEs promoted ovarian cancer metastasis by transferring miR-6780b-5p, a new miRNA, and that inhibition of miR-6780b-5p significantly reduced ovarian cancer cell migration, indicating that exosomal miR-6780b-5p plays an extremely important role in autocrine and paracrine pathways of tumor metastasis. miR-6780b-5p may be the main and common contributing determinant among the various cells in the tumor microenvironment, having value for designing a therapeutic regimen for ovarian cancer metastasis. However, the effect of ADEs cannot be completely explained by the miR-6780b-5p concentration. That is, miR-6780b-5p expression was lowest in #12 ADEs, but large changes in EMT of ADEs cannot be completely explained by the miR-6780b-5p concentration. That is, miR-6780b-5p expression was lowest in #12 ADEs, but large changes in EMT of ADEs cannot be completely explained by the miR-6780b-5p concentration. That is, miR-6780b-5p expression was lowest in #12 ADEs, but large changes in EMT of ADEs cannot be completely explained by the miR-6780b-5p concentration.

In this study, we found that ADEs significantly promoted EMT and metastasis of ovarian cancer cells by transferring miR-6780b-5p. We predicted the function and target genes of miR-6780b-5p. It has been shown that miR-6780b-5p is related mainly to cytoskeletal regulation, the Notch pathway and the MAPK pathway, which are closely related to EMT and tumor metastasis. Consistent with the prediction, we observed that the cancer cells acquired an elongated, dispersed, and more spindle-shaped morphology after treatment with 6780b-5p-rich ADEs (Fig. 2d–e) or miR-6780b-5p agomir (Supplementary Fig. 8). Thus, we elucidated a new molecular mechanism for promoting exosomal miRNAs in ovarian cancer. In addition, the protein components in ADE have not yet been analyzed; therefore, the interaction between different elements in ADEs should be further investigated to illuminate the complicated function of ADEs.

We realize the emerging therapeutic value of exosomes in cancer metastasis. The advantages of exosomes are as follows: first, exosomes provide a relatively stable environment for therapeutic components, and they can be modified specifically on their membrane or in their contents; moreover, the immune response to exosome-based therapies is minimized. An increasing number of studies are focusing on cancer therapy by altering exosomal secretion or composition of noncoding RNAs, including miRNAs. Katakowski Mark et al. reported that intratumoral injection of miR-146b-modified exosomes significantly reduced tumor volume, while the delivery of miR-9-altered exosomes by mesenchymal stem cells reversed drug resistance. In ovarian cancer, exosomes are considered prospective immunotherapies and therapeutic targets modifying the tumor microenvironment. To our knowledge, miR-21 and miR-29a in exosomes of ovarian cancer promote cancer metastasis, while miR-6126 inhibits the invasion and metastasis of ovarian cancer. These miRNAs may be future candidates for ovarian cancer therapy. In this study, we used bioinformatics methods to screen the key miRNAs related to metastasis and finally identified miR-6780b-5p as the key promotive miRNA in ADEs. These results indicate that miR-6780b
Fig. 6 (See legend on next page.)
5p may be an important potential therapeutic target for ovarian cancer metastasis.

In conclusion, ADEs promote ovarian cancer metastasis by transferring miR-6780b-5p to ovarian cancer cells, which leads to EMT of these cells and finally enhances their migration, invasion and proliferation. These findings link exosomes with EMT in ovarian cancer and identify a new key exosomal miRNA that plays important roles in metastasis, providing a new target for ovarian cancer treatment and new insight into the mechanisms underlying metastasis in ovarian cancer.

Acknowledgements
The authors would like to thank Mrs. Yiping Wen (Huazhong University of Science and Technology, Wuhan, China) for the help of primary ovarian cancer cell culture.

Author contributions
J.C. and L.Q.G. conducted most of the experimental work and wrote the manuscript; G.D.L. performed bioinformatics analysis. J.G. conducted the animal experiments and supervised the project. All authors have read and approved the final manuscript.

Ethical statement
The study was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the Research Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China). Written informed consent was obtained from all patients.

Funding
This work was supported by the National Natural Science Foundation of China (Nos. 81903012 and 81772781).

Conflict of interest
The authors declare no competing interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-03490-5.

Received: 29 July 2020 Revised: 30 December 2020 Accepted: 4 January 2021 Published online: 24 February 2021

References
1. Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. Lancet 384, 1376–1388 (2014).
2. Alemans, C. et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 391, 1023–1075 (2018).
3. Bovet, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015).
4. Weidie, U. H., Binzle, F., Kollmorgen, G. & Rueger, R. Mechanisms and targets involved in dissemination of ovarian cancer. Cancer Genomics Proteomics 13, 407–423 (2016).
5. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 67, 7–30 (2017).
6. Lengyll, E. Ovarian cancer development and metastasis. Am. J. Pathol. 177, 1053–1064 (2013).
7. Naora, H. & Montell, D. J. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat. Rev. Cancer 5, 355–366 (2005).
8. Thery, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569–579 (2002).
9. Taylor, D. D. & Geroel-Taylor, C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin. Immunopathol. 33, 441–454 (2011).
10. Wu, M., Wang, G., Hu, W., Yao, Y. & Yu, X-F. Emerging roles and therapeutic value of exosomes in cancer metastasis. Mol. Cancer 18, 53–53 (2019).
11. Vaksman, O., Tropé, C., Davidson, B. & Reich, R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 35, 2113–2120 (2014).
12. Nakamura, K. et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol. Cancer Res. 15, 78–92 (2017).
13. Tang, M. K. S. & Wong, A. S. T. Exosomes: Emerging biomarkers and targets for ovarian cancer. Cancer Lett. 367, 26–33 (2015).
14. Kanlikilicer, P. et al. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res. 76, 7194–7207 (2016).
15. Wu, B. et al. miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OCZ/MEG3/EGFL6 axis. Cell Death Dis. 11, 345–345 (2020).
16. Chen, X. et al. Exosomes derived from hypoxia epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype. Cancer Lett. 435, 80–91 (2018).
17. Wang, L., Zhao, F., Xiao, Z. & Yao, L. Exosomal microRNA-205 is involved in proliferation, migration, invasion, and apoptosis of ovarian cancer cells via regulating VEGFA. Cancer Cell Int. 19, 281–281 (2019).
18. Yokoi, A. et al. Integrated extracellular microRNA profiling for ovarian cancer screening. Nat. Commun. 9, 4319–4319 (2018).
19. Greening, D. W. et al. Emerging roles of exosomes during epithelial-mesenchymal transition and cancer progression. Semin. Cell Dev. Biol. 40, 76–81 (2015).
20. Vergara, D. et al. Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett. 291, 59–66 (2010).
21. Thériault, B. L., Portelance, L., Mes-Masson, A. M. & Nachtigal, M. W. Establishment of primary cultures from ovarian tumor tissue and ascites fluid. Methods Mol. Biol. 1049, 323–336 (2013).
22. Francavilla, C. et al. Phosphoproteomics of primary cells reveals druggable kinase signatures in ovarian cancer. Cell Rep. 18, 3242–3256 (2017).
23. Au Yeung, C. L. et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat. Commun. 7, 11150–11150 (2016).
24. Aung, T. et al. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc. Natl Acad. Sci. USA 108, 15336–15341 (2011).
25. Qin, W. et al. Exosomes in human breast milk promote EMT.
26. Yi, X. et al. EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion. Sci. Rep. 7, 701–706 (2013).
27. Cao, J. et al. miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol. Rep. 30, 1046–2255 (2019).
28. Thery, J. P., Acloue, H., Huang, R. Y. J. & Neto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871–890 (2009).
29. Motohara, T. et al. An evolving story of the metastatic voyage of ovarian cancer cells. J. Cell Biol. 17, 183–194 (2015).
30. Guo, J. et al. Establishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: a comparative study. Int. J. Oncol. 51, 1199–1208 (2017).
31. Gyorffy, B., Lanckzy, A. & Szallasi, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr.-Relat. Cancer 19, 197–208 (2012).
32. Gastpar, R. et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 65, 5238–5247 (2005).
33. Zhu, L. et al. Mesenchymal stem cells-derived exosomes ameliorate nucleus pulposus cells apoptosis via delivering miR-142-3p therapeutic potential for intervertebral disc degenerative diseases. Cell Cycle 19, 1727–1739 (2020).
34. Nagy, A., Lanckzy, A., Menyhárt, O. & Gyorffy, B. Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets. Sci. Rep. 8, 9227–9227 (2018).
35. Mikula-Pietrasik, J., Ursusi, P., Tykarski, A. & Kiszek, K. The pentonel "soil" for a cancerous "seed": a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cell Mol. Life Sci. 75, 509–525 (2018).
36. Motohara, T. et al. An evolving story of the metastatic voyage of ovarian cancer cells cellular and molecular orchestration of the adipose-rich metstatic microenvironment. Oncogene 38, 2885–2898 (2019).
37. Zhou, J. et al. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg/Th17 cell imbalance in epithelial ovarian cancer. Cancer Immunol. Res. 6, 1578 (2018).
38. Han, Q. et al. Tumor cell-fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer. Int. J. Mol. Med. 44, 2246–2255 (2019).
39. Aung, T. et al. Exosomal HIF1[alpha] supports invasive potential of nasopharyngeal carcinoma-associated LMP1-positive exosomes. Oncogene 33, 4613–4622 (2014).
40. Zomer, A. et al. In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell 161, 1046–1057 (2015).
41. Jeppesen, D. et al. Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors. Proteomics 14, 699–712 (2014).
42. Cha, D. J. et al. RASS-dependent sorting of miRNA to exosomes. Life Sciences 4, e07197 (2015).
43. Kruger, S. et al. Molecular characterization of exosome-like vesicles from breast cancer cells. BMC Cancer 14, 44 (2014).
44. Melo, S. A. et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26, 707–721 (2014).
45. Li, W. et al. TGF-β1 in fibroblasts-derived exosomes promotes epithelial-mesenchymal transition of ovarian cancer cells. Oncotarget 8, 96035–96047 (2017).
46. Enriquez, V. A. et al. High LIN28A expressing ovarian cancer cells secrete exosomes that induce invasion and migration in HFK293 cells. Biomed. Res. Int. 2015, 701390–701390 (2015).
47. Georgialopoulou-Soares, I., Chartoumpelis, D. V., Kyiazopoulos, V. & Ziarovinos, A. Tumor markers and metabolic pathways in cancer. Front. Oncol. 10, 499–499 (2020).
48. Yi, Y. et al. Transcriptional suppression of AMPKα1 promotes breast cancer metastasis upon oncogene activation. Proc. Natl Acad. Sci. USA 117, 8013–8021 (2020).
49. Gilligan, K. E. & Dwyer, R. M. Engineering exosomes for cancer therapy. Int. J. Mol. Sci. 18, 1122 (2017).
50. Kellikoglou, I. et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat. Cell Biol. 21, 190–202 (2019).
51. Katakowska, M. et al. Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 335, 201–204 (2013).
52. Li, X. & Wang, X. The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer. Mol. Cancer 16, 92–92 (2017).